Moderna, Pfizer and COVID-19
3h
Zacks Investment Research on MSNHere's Why Moderna Stock Soared 16% on WednesdayShares of Moderna MRNA rose nearly 16% yesterday after a couple of SEC filings showed that two board members bought shares on ...
As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...
After finding support at $30, Moderna (MRNA) added nearly $5.00 to close at $35.21. The firm participated in TD Cowen’s ...
CNET on MSN18h
How the 3 New COVID Vaccines Change the Way You PayNow that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and more.
HHS review of a vaccine contract sparks worries about preparedness for a potential bird flu pandemic
HHS is re-evaluating a nearly $600 million contract with Moderna to develop and test vaccines against flu viruses that could ...
Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results